Spinal Cord Stimulation for Small Fiber Neuropathy
(SAL SFN PILOT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This prospective observational pilot study will evaluate structural, functional, and patient-reported outcomes in adults with small fiber neuropathy who receive Saluda Evoke ECAP-controlled spinal cord stimulation as part of routine clinical care. The study does not assign, direct, or modify spinal cord stimulation therapy. All decisions regarding patient selection, trial stimulation, permanent implantation, and device programming are made independently by the treating physician according to standard clinical practice.
The primary objective is to assess change in intra-epidermal nerve fiber density from baseline to 12 months. Secondary objectives include evaluation of quantitative sensory testing, pain intensity, patient-reported outcomes, and correlations between changes in nerve fiber density, sensory function, and neuropathic pain outcomes.
The study will enroll up to 10 adult participants with clinically diagnosed small fiber neuropathy and chronic neuropathic pain. Research assessments include patient-reported outcome measures, quantitative sensory testing, review of available clinical records, and a 12-month follow-up skin biopsy for intra-epidermal nerve fiber density.
This aligns with the approved protocol: observational, 10 adults, 12-month participant follow-up, primary IENFD endpoint, and secondary QST/pain/correlation endpoints.
Who Is on the Research Team?
Pravardhan Birthi, M.D.
Principal Investigator
TriCity Research Center, LLC
Mahesh Pattabiraman, Ph.D.
Principal Investigator
TriCity Research Center
Are You a Good Fit for This Trial?
This study is for adults diagnosed with small fiber neuropathy and chronic nerve pain who are already receiving spinal cord stimulation as part of their regular care. Participants must be able to complete follow-up visits over a year.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Evoke ECAP-controlled spinal cord stimulation
Trial Overview
The study observes changes in skin nerve fibers, pain levels, and sensory function over 12 months in people using the Evoke spinal cord stimulator. No new treatments or changes to therapy are made; all care decisions remain with each person's doctor.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants with clinically diagnosed small fiber neuropathy and chronic neuropathic pain who receive Saluda Evoke ECAP-controlled spinal cord stimulation as part of routine clinical care will be followed for 12 months. The study does not assign, direct, or modify spinal cord stimulation therapy. All treatment decisions, including trial stimulation, permanent implantation, and device programming, are made independently by the treating physician according to standard clinical practice. Outcomes include intra-epidermal nerve fiber density, quantitative sensory testing, pain intensity, and patient-reported measures.
Find a Clinic Near You
Who Is Running the Clinical Trial?
TriCity Research Center
Lead Sponsor
Saluda Medical Americas, Inc.
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.